IPO - Medical Care Technologies Inc.

Add to your watchlist
Back to List of IPO Filings

Form Type: 253G2

Filing Date: 2025-07-03

Corporate Action: Ipo

Type: Update

Accession Number: 000109991025000181

Filing Summary: Medical Care Technologies Inc. (MDCE) is supplementing its Offering Circular dated April 10, 2025, to announce an increase in the share offering price from $0.00016 to $0.0013 per share. The Company is offering up to 2 billion shares of common stock, with the maximum amount to be raised set at $187,525. Of the offered shares, 557,500,000 have been sold to date, generating proceeds of $135,000. The offering will be conducted under Tier 1 of Regulation A, and no minimum amount needs to be raised to access proceeds. The shares are sold on a 'best-efforts' basis and may continue for up to one year from the offering date. The Company reserves the right to utilize proceeds for various business purposes, including development and operational costs. The shares are highly speculative, with accompanying risks outlined in the offering documentation.

Additional details:

Offering Price: $0.0013


Maximum Amount: $187,525


Number Of Shares Offered: 2,000,000,000


Number Of Shares Sold: 557,500,000


Proceeds To Company: $135,000


Number Of Remaining Shares: 1,442,500,000


Price To Public: $0.0013


Underwriting Discount And Commissions: $0.00


Proceeds To Issuer For Remaining Shares: $187,525


Form Type: CORRESP

Filing Date: 2024-12-04

Corporate Action: Ipo

Type: New

Accession Number: 000109991024000399

Filing Summary: Medical Care Technologies Inc. is requesting to qualify its Offering Statement on Form 1-A, which was filed on August 9, 2024, and has been amended subsequently. The company is seeking qualification of its Regulation A offering to take place on December 5, 2024, at 4 PM Eastern Time, or as soon thereafter as practicable. The document includes confirmations and acknowledgments by the Company regarding the responsibilities of the filing and clarifications about staff comments not serving as a defense in potential proceedings initiated under U.S. federal securities laws. Marshall Perkins III, Chief Executive Officer and Director, signed the letter confirming this request.

Additional details:

Field Name: offering_statement_filed_date

Field Value: 2024-08-09


Field Name: qualification_request_date

Field Value: 2024-12-05


Field Name: contact_phone

Field Value: 480-645-0750


Field Name: contact_attorney_phone

Field Value: 954-903-7856


Comments

No comments yet. Be the first to comment!